Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway. [electronic resource]
Producer: 20130123Description: 949-58 p. digitalISSN:- 1791-2423
- Animals
- Antimetabolites, Antineoplastic -- pharmacology
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Apoptosis -- drug effects
- Cell Cycle Checkpoints -- drug effects
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Deoxycytidine -- analogs & derivatives
- Diterpenes, Kaurane -- pharmacology
- Drug Resistance, Neoplasm
- Drug Synergism
- Female
- Humans
- MAP Kinase Signaling System
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Pancreatic Neoplasms -- drug therapy
- Random Allocation
- Tumor Suppressor Protein p53 -- biosynthesis
- Xenograft Model Antitumor Assays
- p38 Mitogen-Activated Protein Kinases -- biosynthesis
- Gemcitabine
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.